NVIGEN is a nanotechnology empowered personalized medicine innovator.
NVIGEN technology empowers revolutionary personalized medicine with highly accurate and NGS data efficient assays providing integrative DNA, RNA, Protein, and Cell information. Our pipeline of visionary solutions stems from our innovative nanomedicine platform. We are focusing on the development of a comprehensive circulating bio-marker biopsy technology, NVIGEN X™, to predict cancer recurrence at the earliest possible time and guide the most effective personalized therapy.
NVIGEN X™ is enabled by the state-of-the-art molecularly engineered nanoparticles, MagVigen™ and MyQuVigen™, to efficiently capture and identify molecular information from proteins, cells and nucleic acids. We are developing NVIGEN X™ into accurate, automated and FDA approved clinical instruments and reagent kits deployable at hundreds and thousands of hospitals, turning fatal cancers into manageable diseases.
MagVigen™, MyQuVigen™ and MaxVigen™ nanobeads are multifunctional and biodegradable magnetic and/or fluorescent magnetic nanoparticles culminated from 20 years of rigorous research and development at the University of California, Berkeley, Stanford University and NVIGEN.
Along with the development of NVIGEN X™, a milestone we achieved in 2021 is NERNST™-Seq (Nanoparticle Enhanced RNA Spatial and Temporal Sequencing). It utilizes novel nanopipetting technology and can isolate and analyze as little as 1-5% of the RNA content from a single cell (as low as 50fg of material). This highly sensitive RNAseq assay allows us to obtain gene expression data from the target.
We are happy to share the versatility of nanoscience and our 2-decade innovation with the community to develop solutions to empower the advancement of biomedical research and applications in sequencing, biopsy, genomics, diagnostics, gene/cell therapy, and drug delivery etc., with the same goal of providing better cares to patients and enabling healthier lives of every human being.
Both the NVIGEN X® test and the NERNST™-Seq are now open for clinical research use.
Partnerships are a key component of our business development strategy. NVIGEN works closely with our collaborators to develop new technology, products and applications. We are expanding our portfolio through partnerships with researchers, leading pharmaceutical and biotechnology companies. In turn, our partners gain numerous benefits, including access to our cutting-edge IP, product differentiation, enhanced research and development capability, and faster time-to-market.